Piperacillin

證據等級: L5

預測適應症: 9 個

Piperacillin: From Bacterial Infections to Rheumatoid Arthritis

One-Sentence Summary

Piperacillin is a broad-spectrum penicillin-class antibiotic originally used to treat serious bacterial infections caused by susceptible Gram-negative and Gram-positive organisms, typically administered in combination with the β-lactamase inhibitor tazobactam. The TxGNN model predicts it may be effective for Rheumatoid Arthritis (RA), with 0 clinical trials and 18 publications retrieved — however, none of these publications supports piperacillin as a disease-modifying agent for RA. Overall evidence quality is extremely limited, and the prediction is considered a likely model artifact.

Quick Overview

Item	Content
Original Indication	Serious bacterial infections (broad-spectrum penicillin antibiotic)
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	99.94%
Evidence Level	L5
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, Piperacillin is a broad-spectrum ureidopenicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). It is clinically used — almost exclusively in combination with tazobactam — to treat hospital-acquired pneumonia, intra-abdominal infections, complicated urinary tract infections, and febrile neutropenia. There is no known anti-inflammatory, immunomodulatory, or synovial-protective mechanism that would plausibly modify RA disease course.

The mechanistic case for repurposing piperacillin in RA is very weak. Rheumatoid arthritis is driven by autoimmune dysregulation — specifically, aberrant T-cell and B-cell activation, TNF-α, IL-6, and IL-1β signalling, and synovial fibroblast hyperplasia. β-lactam antibiotics have no known activity against any of these pathways. The retrieved literature confirms this gap: every publication featuring piperacillin in an RA context describes its use to treat opportunistic bacterial infections arising in RA patients whose immunity was suppressed by methotrexate, etanercept, upadacitinib, or corticosteroids — not as RA therapy itself.

The most plausible explanation for the high TxGNN score is an indirect knowledge-graph path: RA → immunosuppressive treatment → susceptibility to bacterial infections → antibiotic therapy → piperacillin. This co-occurrence pattern, captured in the knowledge graph, does not reflect a therapeutic relationship. The prediction is most likely a false positive generated by network noise, and the evidence review fully corroborates a Hold decision.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

The 18 retrieved publications do not provide direct evidence for piperacillin as an RA treatment. The table below lists the 10 most informative articles, with annotations explaining how piperacillin actually appears in each context.

PMID	Year	Type	Journal	Key Findings
41257433	2025	Retrospective Cohort	Br J Clin Pharmacol	Machine learning model predicting eosinophilia risk in patients receiving piperacillin/tazobactam — a safety signal, not an RA treatment study
33987340	2021	Retrospective Cohort	Ann Transl Med	Prevalence and characteristics of antibiotic-associated drug-induced liver injury; piperacillin identified as a causative agent — relevant to hepatotoxicity risk, not RA
37599303	2023	Case Report	Orthopadie (Heidelberg)	RA patient on upadacitinib developed prosthetic knee septic arthritis; piperacillin/tazobactam started empirically for pneumonia on admission — infection management, not RA therapy
22605835	2012	Case Report	BMJ Case Reports	RA patient on methotrexate and etanercept developed purulent pericarditis; empirical piperacillin-tazobactam initiated due to raised inflammatory markers — infection treatment, not RA
19621776	2009	Case Report	No Shinkei Geka	Hypertrophic pachymeningitis successfully treated with IV antibiotics including piperacillin; subsequent minocycline reduced CRP — antibiotic context, no RA connection
36945293	2023	Case Report	Cureus	RA patient in remission on sulfasalazine developed recurrent large pleural effusion; neutrophilic leukocytosis noted — no mention of piperacillin as therapy
38343452	2024	Case Report	Proc (Baylor Univ Med Ctr)	Low-dose methotrexate toxicity causing pancytopenia in RA patient; leucovorin rescue — no role for piperacillin
30371923	2019	Case Report	Orthopedics	Bilateral femoral emphysematous osteomyelitis in RA patient on long-term prednisone; treated with IV antibiotics — piperacillin in infection context only
41268563	2025	Case Report	Front Immunol	RA patient on long-term glucocorticoids developed atypical erysipelas by E. coli progressing to septic shock — piperacillin used for infection, not RA
38169875	2023	Case Series	Clin Nephrol Case Stud	Two atypical calciphylaxis cases presenting with ocular ischemic pathology — no direct relevance to piperacillin or RA repurposing

Note: All literature co-occurrences reflect piperacillin’s role in managing infectious complications of immunosuppressive RA therapy, not any disease-modifying effect on RA itself. This pattern is consistent with a knowledge-graph false positive.

Philippines Market Information

Piperacillin is currently not registered with the FDA Philippines. There are no active drug authorizations on record for this compound.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	No registered products found

Piperacillin is available in other markets (typically as piperacillin/tazobactam combination products), but has no current Philippines FDA registration. Any clinical use would require importation under compassionate use or special import permit frameworks.

Safety Considerations

Formal package insert warnings and contraindications data (TFDA/FDA Philippines labelling) were not available in this evidence pack. Based on available literature signals:

Hepatotoxicity Risk: Piperacillin has been identified as a cause of cholestatic drug-induced liver injury (DILI) in retrospective studies (PMID 33987340). This is particularly relevant if repurposing were considered for patients with biliary disease.
Haematologic Adverse Effects: Antibiotic-induced eosinophilia has been documented with piperacillin/tazobactam; a machine-learning risk model was published in 2025 (PMID 41257433).
Nephrotoxicity Potential: Piperacillin/tazobactam carries known risk of acute kidney injury, particularly relevant in patients with pre-existing renal impairment.

Please refer to the full package insert (piperacillin/tazobactam, e.g., Tazocin) for complete warnings, contraindications, and drug interaction information.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no mechanistic, clinical trial, or credible literature evidence supporting piperacillin as a treatment for rheumatoid arthritis. The high TxGNN score (99.94%) almost certainly reflects a knowledge-graph co-occurrence artifact — piperacillin appears in RA-related literature only as an antibiotic used to treat infections in immunocompromised RA patients, not as an RA therapy. Additionally, piperacillin is not registered in the Philippines, there is no established oral formulation for chronic disease management, and the drug’s pharmacological class (β-lactam antibiotic, anti-cell-wall mechanism) has no rational basis for autoimmune disease modification.

For this prediction to move forward, the following would be required:

Mechanistic evidence: Identification of any plausible anti-inflammatory or immunomodulatory pathway by which piperacillin or its metabolites could affect RA pathophysiology (currently none known)
Hypothesis generation: A structured literature review specifically examining whether any β-lactam antibiotic has shown immunomodulatory effects in rheumatological conditions
Model audit: Review of the TxGNN knowledge-graph path that generated this prediction to confirm it is an indirect co-occurrence path (RA → infection → antibiotic) rather than a true therapeutic signal
Philippines regulatory pathway: If future evidence warranted investigation, a compassionate use or special import permit from FDA Philippines would be required given the current zero-registration status

⚠️ Research Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.